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Abstract 
Gene delivery is an important tool to study and manipulate human pluripotent 
stem cells for regenerative medicine purposes. Yet current methods of transient gene 
delivery are still highly inefficient. Using materials and biologically based concepts, we 
aim to develop new methods and protocols to enhance the efficiency of gene delivery to 
be useful. For the materials aspect,  diblock copolymers consisting of poly(ethylene 
glycol)-block-poly(γ-4-(((2-(piperidin-1-yl)ethyl)amino)methyl)benzyl-L-glutamate) (PEG-
b-PVBLG-8) were synthesized and evaluated for their ability to mediate gene delivery in 
hard-to-transfect cells like IMR-90 human fetal lung fibroblasts and human embryonic 
stem cells (hESCs). The PEG-b-PVBLG-8 contained a membrane-disruptive, cationic, 
helical polypeptide block (PVBLG-8) for complexing with DNA and a hydrophilic PEG 
block to improve the biocompatibility of the gene delivery vehicle. PEG-b-PVBLG-8 
diblock polymers with a high degree of polymerization have a greater transfection 
efficiency and lower toxicity in IMR-90 cells than the commercial reagent Lipofectamine 
2000. The usefulness of PEG-b-PVBLG-8 was further demonstrated via the successful 
transfection of hESCs without a measured loss in cell pluripotency markers. From the 
biological aspect, a small molecule that selectively inhibits the Rho-associated kinase 
inhibitor (Y-27632) was discovered that transiently alters the hESC morphology to 
induce spreading and reduced membrane tension. These morphological changes 
allowed the increase of plasmid transfection, siRNA transfection and nanoparticle 
uptake to increase substantially. Treating the cells with Y-27632 and passaging them as 
 iii 
 
single cells, we were able to obtain a transfection efficiency of ~90% in hESCs. Cells 
were also able to recover after treatment back to normal pluripotent stem cell 
morphology and express important pluripotency markers.  
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1. Background 
Human embryonic stem cells hold tremendous potential in the field of regeneration 
due in particular to two characteristics: pluripotency and self-renewal. The former allows 
these cells to differentiate into either the endoderm, mesoderm or ectoderm lineages and 
therefore can transform into virtually any of the cells found in the human body. The latter 
allows the cells to proliferate almost endlessly. This is unlike many of the other cells in 
the human body, which limited and cannot grow as much. This has been a major 
hindrance in regenerative medicine thus far. In order for research in the lab to be an 
applicable technique for biomedical purposes, it is necessary to obtain enough of a certain 
type of cell in order to use it in three dimensions and to encapsulate it into a scaffold to 
be used. The second main property of embryonic stem cells solves this issue of the 
source of the cells and allows one to grow a large quantity of the cells. Once accurate 
control is held over pluripotency as well, tissue engineering could hold much promise. 
Despite the tremendous potential in the application of tissue engineering, there are 
still many caveats and ethical issues in the use of embryonic stem cells. Embryonic stem 
cells are derived from embryos discarded during in-vitro fertilization. Upon entry into the 
blastocyst, the invasive procedure destroys the embryo and thus leads to the biggest 
ethical issue pertaining to human embryonic stem cells; many people believe that the 
destruction of an embryo is considered murder. Another problem, although not of ethical 
nature, that one faces with human embryonic stem cells is its direct clinical application. 
Since these cells were not derived from the patient himself, the actual transplantation of 
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the cell as well as its differentiated lineages could lead to many immunological 
complications. For example, due to an immunological incompatibility, the patient could 
contract what is known as graft-versus-host disease, (GVHD), where the implanted cells 
are rejected, and fail to be grafted in the body.  
There are various roads to pluripotency, the most obvious is where the sperm is 
reprogrammed by the egg upon normal fertilization resulting in a totipotent cell that gives 
rise to the entire embryo proper and to the extra-embryonic tissues. This is the process 
that nature takes and is associated with near perfect efficiency of reprogramming. For 
somatic cells however, this uphill ascent has classically been achieved by one of two 
means: one can introduce nuclei of somatic cells into oocytes, however in this process, 
typically only 5% of cloned embryos develop to term. Nevertheless one can get surviving 
off-spring as in the remarkable case of Dolly the sheep. Or one can do a simple cell fusion 
of somatic cells to ES cells, but the resultant cells, although multipotent by various 
criterion have tetraploid nuclei. In both scenarios, the oocytes/ES cells provide undefined 
trans-acting factors that actively remodel the somatic genome back to a pluripotent state. 
While the former process is saddled by serious ethical and technical concerns, the latter 
process of cell fusion results in the formation of tetraploid cells which have limited clinical 
potential. What would be ideal is an in vitro reprogramming approach where simple 
expression of few factors could directly convert somatic cells into pluripotent stem cells. 
This had until recently been merely fantasy, for the two main problems in using embryonic 
stem cells can also be easily overcome with these in-vitro reprogrammed induced 
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pluripotent stem cells. These cells have been found to look and behave like human 
embryonic stem cells in all forms.  
It has been discovered that pluripotent stem cells have two main states, naïve and 
primed states.1 Mouse embryonic stem cells (mESC) derived from the inner cell mass of 
developing blastocysts are capable of indefinite maintenance in the pluripotent state, 
These mESCs are termed naïve cells, in which they are capable of chimeric embryo 
contribution. There is another type of pluripotent cell lineage that is derived from 
postimplantation epiblast of mouse embryos termed epiblast stem cells (mEpiSCs), in 
which are distinct molecularly and epigenetically from mESCs. These mEpiSCs are 
incapable of chimeric contribution, but able to generate teratomas, demonstrating their 
pluripotent potential, thus termed primed cells. Naïve cells and primed cells demonstrate 
tremendous difference in their growth condition and morphology, in which naïve mESCs 
depend on LIF/Stat3 signaling and grow in a packed dome colony, while primed mEpiSCs 
depend on bFGF and TGFb/Activin signaling and grow in a flattened 2D morphology. In 
addition, it has been found that in contrast to naïve mESCs, primed EpiSCs are intolerant 
to single cell passaging. In addition, gene delivery into naïve ESCs have been found to 
be highly efficient in contrast to the primed EpiSCs. It is possible for the primed mEpiSCs 
to revert back to the naïve mESC state with specific overexpression and growth factor 
treatments. It has been shown that human pluripotent stem cells, both hESCs and hiPSCs 
behave identically to the primed mEpiSCs. In a recent report, it has demonstrated that 
naïve human embryonic stem cells can be rewired to behave like mESCs through gene 
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over expression and controlled growth factors. In addition, they were able to produce 
naïve human induced pluripotent stem cells.2 There have been further studies to further 
efficiently convert the primed hESCs to naïve hESCs for more effective therapeutic 
applications due to their robustness and ease of manipulation. Currently, the process is 
complex and inefficient.  
In the pursuit of regenerative medicine, non-viral gene delivery is an important tool 
to manipulate and control cell fate. One of the newest applications of gene delivery is the 
reprogramming of terminally differentiated cells into induced pluripotent stem cells 
(iPSCs) or, more recently, induced neurons, blood progenitors and cardiomyocytes.3-5 In 
the pioneering work of Yu et al., a recombinant lentivirus carrying the genes for OCT4, 
SOX2, NANOG and LIN28 was used to reprogram IMR-90 fetal lung fibroblasts into 
iPSCs.6 While the resulting iPSCs were characteristically and functionally pluripotent, 
they nonetheless retained remnants of viral DNA as a result of lentiviral integration. This 
could have serious implications if tissue derived from such iPSCs was used 
therapeutically. Non-viral approaches to achieve safe, virus-free reprogramming of IMR-
90 cells using synthetic polymers and lipids, however, have been fruitless as existing 
gene delivery materials have proven to be inefficient at mediating effective gene delivery 
in these cells.  
The genetic manipulation of human embryonic stem cells is an important tool in 
regenerative medicine. The control and over-expression of specific genes afforded by 
gene delivery is valuable not only in efforts to control stem cell fate, but also to study cell 
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behavior in differentiation and gene targeting studies.7 Unfortunately, recent efforts to 
develop new polymeric materials for the non-viral transfection of human embryonic stem 
cell colonies has resulted in only slightly increased efficiency compared to  existing 
commercial products.8 Therefore in my work I have chosen to apply both a materials 
approach and a more biologically cell based approach to develop an efficient gene 
delivery system.  
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2. Cationic, helical polypeptide-based gene delivery for IMR-90 fibroblasts and 
human embryonic stem cells  
2.1 Introduction 
 Both viral and non-viral gene delivery have been explored extensively for basic 
research as well as therapeutic applications. Viral gene delivery is typically more efficient 
than its non-viral counterpart but poses increased risks of immunogenicity, insertional 
mutagenesis and viral integration into the host genome.9 While the integration event 
results in permanent transgene expression—which may not be desirable for all 
applications—it also provides a route for the prolonged expression of undesired viral 
components in host cells. As non-viral gene delivery relies on synthetic polymers or lipids 
and DNA that is explicitly free from viral components, it is generally considered a safer 
alternative than viral gene therapy. Therefore, there is a push to develop non-viral gene 
delivery materials to match the efficiency of viral vectors.10-19 
 Polypeptides were among the first set of materials examined as non-viral gene 
delivery agents.20-22 Given the simplicity in synthesis and formulation with anionic DNA, 
cationic poly(L-Lysine) (PLL) was one of the most intensively studied gene delivery 
polypeptides. However, as a DNA delivery vector, unmodified PLL suffered from low 
transfection efficiency. Even following modification with functional moieties like 
saccharide,23, 24 imidazole25 and guanidinium groups,26 PLL has proven to be an largely 
ineffective gene delivery vector. Nonetheless, there have also been numerous attempts 
to create novel gene delivery vehicles with modified polypeptides, like 
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poly(glycoamidoamine)s27 and HPMA-oligolysines.28  
 Many biologically active peptides share facially amphipathic helical domains as a 
common structural motif.29, 30 Peptides which possess this structure are often able to 
interact with and destabilize the lipid bilayers of cell membranes. In terms of gene delivery, 
cell membrane destabilization can facilitate cell internalization and escape from endocytic 
vesicles.31, 32 PLL and modified PLL, however, adopt random coil structures because 
strong intramolecular side-chain charge repulsion prohibits α-helix formation. As such, 
PLL functions as a conventional polyelectrolyte in gene delivery studies and exhibits 
limited membrane activity.  
 Recently, we reported a new cationic polypeptide possessing a pH-, ionic- and 
temperature-stable cationic helical structure.33 Traditionally, charged polypeptides adopt 
random coil orientations because strong intramolecular side-chain charge repulsion 
prohibits α-helix formation. In our reported polypeptide, termed PVBLGn-8 where n is the 
degree of polymerization, the helical structure is stabilized by increasing the distance 
between the charged side chain groups and the polypeptide backbone. This has the net 
effect of both minimizing the effect of charge repulsion while simultaneously stabilizing 
the helix through hydrophobic interaction between the pendent side chain groups. Our 
prior characterization of PVBLGn-8 peptides as non-viral gene delivery materials revealed 
that the helical structure facilitates strong, disruptive interactions with cell membranes 
which aid the endosomal escape of the endocytosed complexes of polypeptide and 
DNA.34 Although gene delivery with PVBLGn-8 proved to be effective in COS-7 and HEK 
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293 cells with comparable performance to the commercial transfection agent 
Lipofectamine 2000,34 it was largely ineffective in IMR-90 fibroblasts due to its substantial 
toxicity in these cells. Here, we report the design and synthesis of a diblock copolymer 
incorporating polyethylene glycol (PEG) to the PVBLGn-8 polypeptide. We demonstrate 
that the addition of PEG to PVBLGn-8 markedly decreases the toxicity of PVBLGn-8 yet 
preserves the biological activity and gene delivery efficiency of the polypeptide. Moreover, 
with its reduced toxicity, PEG-b-PVBLG-8 is able to effectively transfect IMR-90 
fibroblasts and human embryonic stem cells (Scheme 1), which suggests that it may be 
possible to ultimately achieve higher-reprogramming efficiency of fibroblasts with a safer 
non-viral vector.    
 
2.2 Materials and Methods 
2.2.1 General 
 All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) and used 
as received unless otherwise specified. Anhydrous dimethylformamide (DMF) was dried 
by a column packed with 4Å molecular sieves and stored in a glovebox. Tetrahydrofuran 
(THF) and hexane were dried by a column packed with alumina and stored in a glove 
box. OptiMEM and Lipofectamine 2000 were purchased from Invitrogen (Carlsbad, CA, 
USA). pEGFP-N1 was obtained from Elim Biopharmaceuticals (Hayward, CA, USA). The 
human embryonic stem cell line H1 was cultured in mTeSR 1 medium from Stem Cell 
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Technologies (Vancouver, Canada). Milli-Mark™ Anti-SSEA-4-PE were purchased from 
EMD Millipore (Billerica, MA, USA). IMR-90 fetal lung fibroblast cells were purchased from 
ATCC (Manassas, VA, USA) and cultured in MEM containing Earle’s balanced salt 
solution supplemented with 10% fetal bovine serum. L-glutamic acid copper(II) complex 
copper(II) salt tetrahydrate35 and -(4-vinylbenzyl)-L-glutamate N-carboxyanhydride (VB-
Glu-NCA)33, 36 were prepared by following previously reported procedures. 
 
2.2.2 Instrumentation  
 NMR spectra were recorded on a Varian UI400 MHz, a UI500NB MHz or a VXR-
500 MHz spectrometer. Tandem gel permeation chromatography (GPC) experiments 
were performed on a system equipped with an isocratic pump (Model 1100, Agilent 
Technology, Santa Clara, CA, USA), a DAWN HELEOS 18-angle laser light scattering 
detector (also known as multi-angle laser light scattering (MALLS) detector, Wyatt 
Technology, Santa Barbara, CA, USA) and an Optilab rEX refractive index detector 
(Wyatt Technology, Santa Barbara, CA, USA). The detection wavelength of HELEOS was 
set at 658 nm. Separations were performed using serially connected size exclusion 
columns (100, 500, 103 and 104 Å Phenogel columns, 5 µm, 300 × 7.8 mm, Phenomenex, 
Torrance, CA, USA) at 60 °C using DMF containing 0.1 M LiBr as the mobile phase. The 
MALLS detector was calibrated using pure toluene with no need for external polymer 
standards and was used for the determination of the absolute molecular weights. The 
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molecular weights (MWs) of all polymers were determined based on the dn/dc value of 
each sample calculated offline by using the internal calibration processed by the ASTRA 
V software (version 5.1.7.3, Wyatt Technology, Santa Barbara, CA, USA). Infrared 
spectra were recorded on a Perkin Elmer 100 serial FTIR spectrophotometer equipped 
with universal attenuated total reflectance (ATR), which enabled the analysis of polymer 
samples in powder form. Circular dichroism (CD) measurements were carried out on a 
JASCO J-700 or a JASCO J-720 CD Spectrometer. Ozone was produced by an OZV-8S 
ozone generator manufactured by Ozone Solutions Inc. (Hull, IA, USA). Lyophilization 
was performed on a FreeZone lyophilizer (Labconco, Kansas City, MO, USA). Flow 
cytometry analysis was conducted on a BD FACSCanto 6 color flow cytometry analyzer 
(Becton Dickinson, Franklin Lakes, NJ, USA). Cells were visualized with a Zeiss Axiovert 
40 CFL fluorescence microscope equipped with a 20 objective (Thornwood, NY, USA). 
Zeta potential and particle size were analyzed with a Malvern Zetasizer (Worcestershire, 
UK).  
 
2.2.3 General procedure for the polymerization of VB-Glu-NCA 
 We followed previously established procedure to synthesize and polymerize NCAs 
to prepare polypeptides.37-40 In a glovebox, VB-Glu-NCA (56 mg, 0.2 mmol) was dissolved 
in DMF (1 mL) followed by the addition of PEG-amine and 1,5,7-triazabicyclo[4.4.0]dec-
5-ene (TBD) at various monomer:amine:TBD ratios (Table 1). The polymerization 
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solutions were stirred at room temperature for 24-60 h until VB-Glu-NCA was consumed. 
Aliquots of the polymerization solutions were diluted to 10 mg polymer/mL using DMF 
containing 0.1 M LiBr and analyzed by GPC. The real-time concentration of NCA was 
quantified by measuring the intensity of the anhydride band at 1784 cm-1 by FTIR. The 
conversion of VB-Glu-NCA was determined by comparing the VB-Glu-NCA concentration 
in the polymerization solution versus the initial VB-Glu-NCA concentration. When the 
polymerization was complete, the majority of the DMF was removed under vacuum and 
the polymer was precipitated with ether (15 mL). The resulting PEG-b-PVBLG polymer 
was sonicated in ether for 5 min and centrifuged to remove remaining solvent. After the 
sonication-centrifugation steps were repeated two more times, PEG-b-PVBLG was 
collected and dried under vacuum (44 mg and 75% yield, and 35 mg and 68% yield for 
PEG113-b-PVBLG76 and PEG113-b-PVBLG287, respectively). 1H NMR (TFA-d, 500 MHz): 
 7.53 (d, 2H, J =7.0 Hz, ArH), 7.39 (d, 2H, J =7.0 Hz, ArH), 6.84 (dd, 1H, J1 =11.0 Hz, J2 
=18.0 Hz C6H4CH=CH2), 5.91 (d, 1H, J =18.0 Hz, C6H4CH=CH2), 5.43 (d, 1H, J =11.0 Hz, 
C6H4CH=CH2), 5.26 (m, 2H, ArCH2), 4.80 (m, 1H, CHCH2CH2COOCH2), 4.13 (m, -
OCH2CH2- in PEG), 2.68 (m, 2H, CHCH2CH2COO), 2.30 (m, 1H, CHCH2CH2COO), 2.12 
(m, 1H, CHCH2CH2COO).   
 
2.2.4 General procedure for the synthesis of poly(ethylene glycol)-block-poly(γ-(4-
aldehydebenzyl)-L-glutamate) (PEG-b-PABLG)   
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 PEG-b-PVBLG (40 mg) was dissolved in chloroform (30 mL) at -78oC. Oxygen was 
then bubbled into the solution for 1 min followed by the bubbling of ozone until the solution 
became blue. The ozone was then replaced by oxygen, which was bubbled into the 
solution for 2 min until the solution became colorless. The solution was degassed and 
back filled with nitrogen. Dimethyl sulfide (1 mL) was then added and the solution was 
stirred at room temperature overnight. Afterwards, the solvent was removed under 
vacuum and the resulting PEG113-b-PABLG76 was purified by sonicating the polymer in 
methanol (3 × 15 mL) and collected by centrifugation. PEG113-b-PABLG76 was dried under 
vacuum (33 mg, 82% yield). PEG113-b-PABLG287 was synthesized from PEG113-b-
PVBLG287 by following the similar procedure for synthesis of PEG113-b-PABLG76 with 86% 
yield. 1H NMR (TFA-d, 500 MHz):  10.31 (1H, CHOC6H4), 8.40 (d, 2H, J =7.0 Hz, ArH), 
7.96 (d, 2H, J =7.0 Hz, ArH), 5.71 (2H, CHOC6H4CH2), 5.21 (1H, CHCH2CH2CO2CH2), 
4.10 (m, -OCH2CH2- in PEG), 3.12 (2H, CHCH2CH2), 2.75 (1H, CHCH2CH2), 2.56 (1H, 
CHCH2CH2).  
 
2.2.5 General procedure for the preparation of PEG-b-PVBLG-8   
 PEG-b-PABLG (20 mg), N-(2-aminoethyl)piperidine (5 molar equiv relative to the 
Glu repeating unit of PEG-b-PABLG) and borane-pyridine complex (5 molar equiv) were 
mixed in DMF (3 mL) and stirred at 50oC for 48 h (Table 2). The mixture was poured into 
3 M HCl (3 mL) and dialyzed against water for 48 h. The resulting PEG-b-PVBLG-8 was 
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lyophilized. The yields of PEG-b-PVBLG-8 copolymers were between 60 and 70%, with 
grafting efficiencies greater than 95%, which was determined as previously reported.34   
 
2.2.6 General procedure for the analysis of polypeptide conformations by circular 
dichroism (CD)  
 Circular dichroism studies were performed on JASCO J-700 and J-720 CD 
spectrometers. Samples were prepared at polymer concentrations of 0.01-0.1 mg/mL 
unless otherwise specified. In a representative experiment, the sample solution was 
placed in a quartz cell with a path length of 0.5 cm and the mean residue molar ellipticity 
of the polymer was calculated based on the measured apparent ellipticity according to 
the equation: Ellipticity ([θ] in deg·cm2·dmol-1) = (millidegrees × mean residue 
weight)/(path length in millimeters × concentration of polypeptide in mg·mL-1).41 For helix-
temperature dependency studies, the temperature of the sample chamber containing the 
quartz cell was varied from 4 to 70oC using a water bath. A minimum of 10 min was 
allowed for sample temperature equilibration prior to collecting CD measurements. The 
α-helix contents of the polypeptides were calculated using the following equation: % α-
helix = (-[]222 + 3000)/39,000.42 
 
2.2.7 Agarose gel retardation  
 A solution of DNA (0.5 µg) was prepared in OptiMEM (50 µL). Separately, a 
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solution of polypeptide in OptiMEM (50 µL) was prepared to achieve the desired 
polypeptide:DNA weight ratio. Following mixing of the two solutions, complexes were 
incubated at room temperature for 20 min, after which an aliquot (20 µL) was withdrawn 
and loading dye (4 µL) was added. The mixture was then run on a 2% agarose gel (100 
V, 60 min). DNA was stained with ethidium bromide and visualized on a Gel Doc imaging 
system (Biorad, Hercules, CA, USA)  
 
2.2.8 Characterization of polymer/DNA complex with zeta potential and dynamic 
light scattering 
Solutions of DNA (25 µg) were prepared in OptiMEM (400 µL).  Separately, a 
solution of polypeptide (1 mg) was prepared in OptiMEM (400 µL). A solution of 
Lipofectamine 2000 (50 µL, 1 mg/mL) in OptiMEM (400 µL) was also prepared as a 
control. The DNA solution was then mixed with either the polypeptide or Lipofectamine 
2000 solution and allowed to incubate at rt for 20 min.  The size and surface charge of 
the resulting polyplexes were analyzed by dynamic light scattering (DLS) and zeta 
potential. 
 
2.2.9 Transfection of IMR-90 with Lipofectamine 2000 and PVBLG-8 Polymers 
IMR-90 cells were seeded at 50,000 cells per well in 24-well plates one day prior 
to transfection. On the day of transfection, plasmid pEGFP-N1 DNA (1 μL, 1 mg/mL) was 
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diluted with OptiMEM (50 μL). Separately, Lipofectamine 2000 (2 μL, 1 mg/μL) or the 
polymer solution (10-80 µL, 1 mg/mL) was diluted with OptiMEM (50 μL). The individual 
solutions were then mixed gently and allowed to incubate for 5 min at rt, after which they 
were combined and allowed to incubate at rt for another 20 min. The cell media was then 
aspirated and replaced with pre-warmed (37°C) OptiMEM (500 μL). The complex solution 
was added dropwise to the cells. The cells were then incubated at 37°C with 5% CO2 for 
4 h, after which the cell media was replaced with normal culture media (500 μL). After 
incubation for a total of 48 h at 37°C with 5% CO2, the cells were imaged with a fluorescent 
microscopy.  The EGFP transfection efficiency was quantified by flow cytometry.  
 
2.2.10 Sample preparation and flow cytometry analysis 
Prior to analysis by flow cytometry, transfected cells on the 24-well plate were 
washed with 1 PBS (500 μL for each well) to remove any residual serum, dead cells and 
debris. Next, trypsin (100 µL) was added and incubated for 5-10 min to detach the cells 
from the plate. PBS (100 µL) was then added and pipetted up and down to break up cell 
clumps. A solution of 4% paraformaldehyde (100 µL) was added to fix the cells. Samples 
were kept in covered flow cytometry tubes until analysis (BD FACSCanto, Franklin Lakes, 
NJ, USA). 
 
2.2.11 MTT assay of polymers 
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 For MTT assays, 10,000 cells were seeded in each well of a 96-well plate one day 
before transfection. The cells were then transfected as described above, save for an 80% 
reduction in volume and reagent quantity to accommodate the reduced well volume. The 
cells were incubated for 4 h at 37°C in the transfection mix before being returned to fresh 
growth media. After 48 h, the cells were washed with PBS and MTT solution was added. 
Following 4-h incubation at 37°C, MTT solubilization solution (10% Triton X-100 in acidic 
(0.1M HCl) isopropanol) was added to the cells and the absorbance of 570 nm light was 
quantified on a Perkins Elmer plate reader (Waltham, MA, USA). 
 
2.2.12 hESC transfection 
 hESCs were seeded in Matrigel-coated 24-well plates. Plasmid DNA (1 µL, 
1mg/mL) was diluted in OptiMEM (50 µL). The polymer solution (10-40 µL, 1 mg/mL) was 
diluted with OptiMEM (50 µL). The two solutions were then vortexed gently and allowed 
to incubate for 5 min at rt, after which they were combined and allowed to incubate for 
another 20 min at rt. Next, the mixtures were added to the cells dropwise and allowed to 
incubate at 37°C for 4 h. The media was then aspirated and fresh media was added. After 
48 h, the cells were stained with DAPI (250 µL, 3 nM) and SSEA-4 –PE (250 µL, 0.02 
mg/mL), a pluripotency cell marker, for 30 min at 37 °C.  
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2.3 Results 
2.3.1 Synthesis and characterization of PEG-b-PVBLG-8 (PEV)  
 -(4-Vinylbenzyl)-L-glutamate N-carboxyanhydride (VB-Glu-NCA) was prepared 
by following previously reported methods.33, 34, 36 The ring-opening polymerization of VB-
Glu-NCA with PEG-amine as the macroinitiator yielded PEG-block-poly(-(4-vinylbenzyl)-
L-glutamate) (PEG-b-PVBLG) with controlled molecular weights (MWs) and narrow 
molecular-weight distributions (Scheme 2). At the VB-Glu-NCA/PEG-amine ratio of 100, 
the obtained Mn of 20.7 × 103 gmol-1 agreed well with the theoretical Mn of 24.6 × 103 
gmol-1 and had a narrow molecular weight distribution of 1.21 (entry 1, Table 1). Two 
PEG-b-PVBLG copolymers were prepared with degrees of polymerization (DP) of 76 
(PEG-b-PVBLG76) and 287 (PEG-b-PVBLG287) of the PVBLG block (Table 1). The 
ozonation of PEG-b-PVBLG yielded PEG-b-poly(-(4-aldehydebenzyl-L-glutamate) 
(PEG-b-PABLG), which served as the reactive intermediate that, through subsequent 
hydroamination and reduction with N-(2-aminoethyl)piperidine, yielded the desired PEG-
b-PVBLG76-8 (PEV-L) and PEG-b-PVBLG287-8 (PEV-H). Grafting efficiencies of greater 
than 95% were achieved for both PEV-L and PEV-H (Table 2).  
 Both PEV-L and PEV-H are highly soluble in water at pH 1-10 (> 50 mg/mL), which 
is drastically different from the corresponding parental (PEG-b-PVBLG) and intermediate 
polymers (PEG-b-PABLG) that are insoluble in water. The excellent water solubility of 
PEV-L and PEV-H is clearly related to their charged side groups, which make it possible 
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for the applications of PEV at physiological pH.  Both PEV-L and PEV-H showed the 
characteristic CD spectra of an -helix with two minima at 208 and 222 nm (Fig. 1a), 
consistent with our previously reported α-helical conformation of PVBLG-8.34, 43  Helical 
contents of greater than 90% were observed for both PEV-L and PEV-H at pH 3 when 
the side chain amine groups are protonated (Table 2). As expected, the charge repulsion 
of the side groups had minimal effect on helix stability because the charged amine groups 
were placed far away from the polypeptide backbone. Furthermore, the helicity—as 
measured by the value of -[]222—was shown to be stable against pH and salt changes 
in the surrounding environment. For example, the -[]222 values of PEV-L and PEV-H 
remained unchanged when the solution pH was increased from 1 to 9 (Fig. 1b).  The 
helices of PEV-L and PEV-H were also fairly stable in concentrated denaturing conditions, 
such as in 1M NaCl (Fig. 1d) and 2M urea (Fig. 1d) aqueous solutions. These 
observations suggested that PEVs would maintain their helical conformation in various 
extracellular and intracellular environments with well-preserved properties throughout the 
gene transfection processes.  
 
2.3.2 Complex formation with PEG-b-PVBLG-8 with DNA 
 The ability of PEG-b-PVBLG-8 to bind and complex with DNA was examined using 
a gel retardation assay. Polymer was mixed with plasmid DNA at DNA:polymer weight 
ratios between 1:1 and 1:60 and run on an agarose gel. The results for PEV-L can be 
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seen in Fig. 2. The addition of polymer in excess of a 1:2 (DNA:polymer weight ratio) 
resulted in the formation of stable complexes which prohibited the migration of DNA under 
an electrophoretic  force. Interestingly, at a 1:2 DNA:polymer weight ratio, the DNA could 
still be seen in the loading well, indicating incomplete condensation. However, the DNA 
was no longer visible when sufficient polymer was added to achieve a 1:10 DNA:polymer 
weight ratio, indicating complete condensation. As can be seen in Fig. 1a, DNA binding 
does not affect the α-helicity of the peptide. 
 
2.3.3 Dynamic light scattering 
 Dynamic light scattering revealed complexes formed between DNA and 
Lipofectamine 2000 at a 1:2 DNA:Lipofectamine 2000 weight ratio to be approximately 
574 nm in diameter. Meanwhile, the hydrodynamic diameter of complexes of PEV-L and 
PEV-H at a 1:40 DNA:polymer weight ratio were substantially smaller—about 107 nm and 
246 nm for PEV-L and PEV-H, respectively (Fig. 4). Testing of DNA:polymer weight ratios 
less than and greater than 1:40 did not dramatically change the measured diameter—
provided a minimum amount of polymer was added to achieve complexation. For 
example, the diameter of complexes made with DNA:PEV-L weight ratios of 1:10, 1:20, 
1:40 and 1:80 were 117 nm, 115 nm, 107 nm, and 84 nm, respectively. This suggests 
that once a minimum amount of polypeptide is present—presumably enough to achieve 
a 1:10 DNA:polymer weigh ratio based on Fig. 2—the excess polymer is not incorporated 
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into the complex and exists freely in the solution. Furthermore, despite the rod-like 
structure of the helical polypeptide, complexes formed between DNA and PEG-PVBLG-
8 possessed a globular structure under TEM (Fig. 3). Zeta potential measurements were 
performed to ensure that the complex formed between PEV-L (or PEV-H) and DNA were 
overall positively charged. PEV/DNA complexes formed possessed zeta potentials 
between 2 and 10 mV (Fig. 5), while PVBLG-8/DNA complexes possessed zeta potentials 
between 20 and 30 mV (data not shown). The addition of PEG block to the polypeptide 
shielded the cationic charge of the PVBLG-8 block.  
 
2.3.4 Toxicity 
 The toxicity of the PEV-H was compared with PVBLG-8 homopolymer (P0) and 
Lipofectamine 2000 via MTT assays in IMR-90 cells. PVBLG-8 (P0) was found to be 
notably toxic to IMR-90 cells.  At 1:40 DNA:polymer weight ratio, a viability of 6% was 
observed.  The new diblock polymers of both low (PEV-L) and high (PEV-H) molecular 
weight showed substantially reduced toxicity to IMR-90 cells (Fig. 6). Increasing 
DNA:polymer ratio resulted in increased toxicity for both PEV-L and PEV-H polymers. 
PEV-H/DNA complexes showed slightly reduced toxicity compared to PEV-L/DNA 
complex, but both PEV-L- and PEV-H polymers were less toxic than Lipofectamine 2000 
under similar condition.   
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2.3.5 Transfection 
 Transfection experiments were performed with the diblock co-polymers to 
determine if their reduced toxicity impacted their ability to effectively delivery genes to 
IMR-90 cells. As shown in Fig. 7, the commercial reagent Lipofectamine 2000 resulted in 
approximately 19% of treated cells expressing the delivered GFP transgene. Unmodified 
PVBLG-8 (P0), on the other hand, had a transfection efficiency of only 1.4% with low cell 
viability. While PVBLG-8 performed comparable to Lipofectamine 2000 in COS-7 and 
HeLa cells in previous studies, its poor performance as shown in Fig. 7 is likely due to the 
excessive toxicity of the polypeptide in IMR-90 cells. Reducing the toxicity of PVBLG-8 
through the addition of PEG blocks resulted in an increased IMR-90 transfection efficiency 
to 9.4% and 21.4% for PEV-L and PEV-H, respectively. Because of the reduced toxicity 
of PEV-L and PEV-H, the DNA dosage could be increased from 1 µg to 2 µg, which 
resulted in slightly higher transfection efficiencies, 13% and 27%, for PEV-L and PEV-H 
formulations, respectively (data not shown). Although this increase in efficiency was 
modest, it should be highlighted that the diblock polymers appeared to have reduced 
toxicity. For example, even though both Lipofectamine 2000- and PEV-H-transfected cells 
expressed similar amount of GFP in Figure 8, the cells transfected with PEV-H possessed 
an overall healthier phenotype with flat and elongated shapes as opposed to cells 
transfected with Lipofectamine 2000 that appeared to be sparse and rounded. 
 To further demonstrate the application of PEG-b-PVBLG-8, we next evaluated the 
gene delivery efficiency to the H1 hESCs. PEV-H transfection in separated H1 cells 
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resulted in higher transfection efficiency than in cells plated as colonies (Fig. 9, 10). 
Moreover, the polymer was shown to have no impact on hESC pluripotency 48 h post-
transfection. This was evidenced by the similar expression of stage specific embryonic 
antigen-4 (SSEA-4) both before and after transfection in colonies and single cells (Fig. 
12). Further evidence of pluripotency was shown through a western blot of the OCT4 
pluripotency transcription factor before and after transfection with PEV-H (Fig. 11). 
Combined with its efficiency, the mild cell impact of the PEV-H made it a promising 
reagent to manipulate the gene expression of human stem cells. 
 
2.4 Discussion 
 Transfection efficiency is often limited due to the toxicity of vectors. Generally, the 
more efficient the transfection material, the greater impact it may have on cell health. This 
is largely due to the requirements of effective gene delivery—namely, a high polycationic 
charge to condense DNA and enable cell surface binding and membrane-lytic properties 
to facilitate intracellular escape from endocytic vesicles. While good for the delivery of 
nucleic acids, highly cationic materials can also bind and interfere with the function of 
necessary proteins within the cell. Moreover, the membrane lytic effect of materials can 
be unspecific and may act in desirable as well as undesirable manners. Effective gene 
delivery materials are able to balance their positive and negative tendencies so that they 
are efficient enough to allow macromolecules like DNA to enter the cells but safe enough 
that the cells are not irreparably damaged during the process. In this paper, we focus on 
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the previously described PVBLG-8 materials and try to reduce their overall toxicity while 
maintaining their effective gene delivery performance. 
 Previous characterization of the helical polypeptide PVBLG-8 revealed that it can 
operate as an effective delivery vector for both DNA and siRNA.34 In both cases, its 
performance was demonstrated to be tied to its ability to form stable helices that cause 
pore formation within membranes. In the case of DNA delivery, the membrane lytic 
potential was essential to the escape of DNA-polypeptide complexes from endocytic 
vesicles. In the case of siRNA delivery, the helical PVBLG-8 caused pore formation within 
cells membranes to allow the non-endocytic diffusion of siRNA into the cell cytosol. 
Therefore, in our desire to reduce the toxicity of the PVBLG-8 materials, it was also 
essential to retain their helical structure. Unfortunately, just as helicity makes the 
materials effective delivery agents, it is also a contributing factor to overall toxicity. As 
such, we sought a strategy to append charge shielding materials to the helical PVBLG-8. 
By shielding the positive charge, we hoped to minimize the toxicity of the material by 
reducing its electrostatic attraction with negatively charged cell membranes. At the same 
time, since the helicity of the PVBLG-8 block was maintained (Fig. 1a), we hoped that the 
material would retain its ability to effectively escape endosome and mediate effective 
gene delivery (Scheme 1).  
 To test the feasibility of incorporation of charge shielding groups, PEG was 
covalently conjugated with PVBLG-8 to yield the diblock polymer PEG-b-PVBLG-8. The 
PEG used had a MW of 5000 Da (DP of 113) and was conjugated to helical PVBLG-8 
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with DPs of 76 and 287 to yield the diblock materials PEV-L and PEV-H, respectively 
(Scheme 2). Circular dichroism experiments revealed that the incorporation of PEG did 
not alter the presence and stability of the helices even after the DNA is bound and 
condensed by the peptide (Fig. 1a). Moreover, the materials were also able to bind and 
condense plasmid DNA into spherical particles with diameters on the order of 100 nm 
(Fig. 2–4). Despite the inclusion of PEG, these particles were demonstrated to retain an 
overall positive surface charge similar to commercial materials like Lipofectamine 2000 
by analyzing their surface zeta potential (Fig. 5). 
 Toxicity measurements with the diblock materials revealed that the inclusion of a 
PEG block substantially increased the biocompatibility of the materials in IMR-90 cells. 
For example, treatment with the unmodified PVBLG-8 left only approximately 5% of IMR-
90 cells viability. However, with the addition of a PEG block, cell viability increased 
dramatically and was less toxic than Lipofectamine 2000 (Fig. 6). With its improved 
toxicity profile, PEG-b-PVBLG-8 was able to mediate effective transfection in IMR-90 
cells. Previously, the toxicity of the materials was so extreme that only 1.4% of cells were 
successfully transfected. With the reduced toxicity, that number was increased to 
approximately 20%—an increase of approximately 14-fold. With its improved safety 
profile, PEG-b-PVBLG-8 was mild enough to transfect H1 human embryonic stem cells 
without affecting the expression of cell pluripotency markers (Fig. 9-12).  
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2.5 Conclusion 
We prepared diblock copolymers consisting of poly(ethylene glycol)-block-poly(γ-
4-(((2-(piperidin-1-yl)ethyl)amino)methyl)-benzyl-L-glutamate) (PEG-b-PVBLG-8) and 
evaluated their capability to mediate gene delivery in IMR-90 human fetal lung fibroblasts 
and human embryonic stem cells (hESCs). The PEG-b-PVBLG-8 contained a membrane-
disruptive, cationic, helical polypeptide block (PVBLG-8) for complexing with DNA and a 
hydrophilic PEG block to improve the biocompatibility of the gene delivery vehicle.  PEG-
b-PVBLG-8 copolymers with low (n = 76) and high (n = 287) degrees of polymerization 
(n) of the PVBLG-8 block were synthesized. We found that the incorporation of PEG 
effectively reduced the toxicity of the helical PVBLG-8 block without dramatically 
compromising the complexation of copolymers with DNA and their transfection 
efficiencies. PEG-b-PVBLG-8 diblock polymer with a high degree of polymerization had 
a greater transfection efficiency and lower toxicity in IMR-90 cells than the commercial 
reagent Lipofectamine 2000. The usefulness of PEG-b-PVBLG-8 was further 
demonstrated via the successful transfection of hESCs without a measured loss in cell 
pluripotency markers. In contrast to many other polymer- and lipid-based transfection 
systems which utilize the proton sponge mechanism (e.g. polyethylenimine) or lipid 
mixing (e.g. DOTAP, DOPE, etc.) to facilitate endosomal escape, the peptides described 
here make use of a novel pore formation mechanism.  As endocytic escape is generally 
considered one of the most challenging aspects of gene delivery, this alternative 
endosomolytic mechanism may prove useful when working with cell lines not readily 
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amenable to transfection by current methods (i.e. IMR-90 and hES cells). As both IMR-
90 and hESCs are important cell lines that are commonly used in the field of regenerative 
medicine, effective non-viral gene delivery to these cells is an important step in bringing 
regenerative medicine closer to clinical applications. 
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3. Small molecule enhanced gene delivery into human embryonic stem cells 
3.1 Introduction 
In the previous chapter, we have demonstrated human embryonic stem cell 
transfection using a material design approach. In this chapter, a more biological and 
cellular approach will be explored. Human embryonic stem cells are round and mildly stiff 
in structure due to the fact that they grow in colonies and prefer to grow in a rounded up 
shape with intrinsic tension. hESCs grow in tight two dimensional colonies, where the 
cells in the center are often compressed by the surrounding cells. This compression of 
the cells at the center of the colonies would limit their exposure to the cell medium and 
their uptake abilities of any nanocomplexes, this can be seen in our gene delivery studies 
in the previous chapter, in which the outer edge of the cells seem to have the highest 
uptake efficiency. These physical properties of the hESC colony growth can be a limitation 
in gene delivery efficiency that may not be able to be solved through the material science 
route of the vector design. We thus investigated potential avenues to transiently 
manipulate the hESC morphology to better allow their uptake for nanocomplexes. 
Based on primed and naïve pluripotent stem cell studies, the cellular state can be 
an important aspect and factor to increase the efficiency of gene delivery and 
manipulation of hESCs in addition to the materials aspect. In this chapter, novel ways 
were investigated for cell manipulation to transiently alter the cellular physiology to 
increase transfection efficiency.  
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Knowing that substrate stiffness plays an important role on gene transfection 
efficiency, 44 We hypothesize that cell uptake is intrinsic to the stiffness and structure of 
the cells. A decrease in membrane tension and contractility would lead to increase cellular 
spreading45 and also stimulates endocytosis.46 Therefore, we decided to use a selective 
Rho-associated kinase (ROCK) inhibitor, Y-27632, to alter the cell’s myosin fibers to 
mimic the cell's structure when grown on a stiffer substrate47, 48. ROCK inhibitor has been 
shown to inhibit p160-Rho associated coiled-coil kinase, a pathway upstream of non-
myosin IIA.  
As described earlier, hESCs are considered to be in the primed state, thus 
intolerant to single cell passaging, for they usually only exhibit <1% clonal efficiency, due 
to apoptosis upon cellular detachment and dissociation. Rho inhibitor has been used to 
diminish dissociation induced apoptosis, and cause the increase of the survival of 
individual hESCs 49. The group found by pre-treatment of the hESCs with Y-27632 (10 
µM) for an hour before single cell dissociation, and then replated, they found that the 
cloning efficiency increased to 27%. The treatment with Y-27632 demonstrates Cells 
treated with Y-27632 demonstrated to maintain their pluripotency and morphology for at 
least 5 passages and were able to differentiate into neural cells. 49 
In our hands, we discovered that not only does the Y-27632 decrease apoptosis 
during single cell passaging, when it is added to the media, the cells started spreading 
and attaching to the plate. The colonies do not maintain its tight 2D colony, but adopts a 
loose spread out colony. We conducted gene transfection on this new transitional state 
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to determine if this spreading would increase transfection efficiency potentially due to the 
reduce tension of the cell membrane.   
 
3.2 Materials and Methods 
3.2.1 hESC Transfection with Rho Inhibitor  
hESCs were seeded in Matrigel-coated 24-well plates. On the day of transfection, 
4 hours before transfection, the cells were changed to media with 0X, 1X, 3X or 5X of Y-
27632 (10 uM working concentration). Then after 4 h, plasmid DNA (1 µL, 1mg/mL) was 
diluted in OptiMEM (50 µL). The transfection reagent, Lipofectamine or FHD (2-3.5 μL, 1 
mg/mL) was diluted with OptiMEM (50 µL). The two solutions were then vortexed gently 
and allowed to incubate for 20 min at rt, after which they were combined and allowed to 
incubate for another 20 min at rt. Next, the mixtures were added to the cells dropwise and 
allowed to incubate at 37°C for 4 h. The media was then aspirated and fresh media was 
added. For the pre-treatment samples, the first 4 h prior transfection was in media with 
5X Y-27632 and changed to normal media prior to transfection. For the post-treatment 
sample, the first 4 hours before transfection was in normal media, but prior to transfection, 
the media was change to media containing 5X Y-27632. After 48 h, the cells were stained 
with DAPI (250 µL, 3 nM) and SSEA-4 –PE (250 µL, 0.02 mg/mL), a pluripotency cell 
marker, for 30 min at 37 °C.  
 
3.2.2 siGLO Green Delivery into hESC 
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Two wells of a 6 well plate of hESC H1s or WA01 OCT4 GFP KI H1 were plated 
into a 24 well plate coated with Matrigel a day or two before transfection. Y-27632 at 0x, 
1x or 3x were added to the cells 4 hours before transfection. For transfection with 
Lipofectamine 2000 with incubation, siGlo Green (30 picomoles) was added to Optimem 
(50μL) and Lipofectamine (1μL, 1 mg/mL) was added to another tube of Optimem 
(50μL). The two solutions were mixed and incubated at room temperature for 20 
minutes and added directly to the cells. For the alternative method instead of mixing the 
two solutions, the polymer solution was added directly to the cells first and then the 
solution containing the siGlo Green was added separately to the cells right after. The 
cells were incubated for either 48 hours and collected and analyzed with flow cytometry.  
 
3.2.3 RITC Silica nanoparticle synthesis  
Methanol (1.0 mL), DI water (0.27 mL), and concentrated ammonia (0.24 mL) 
were mixed. TEOS (62.5 μL, 0.28 mmol) was then added to the solvent mixture followed 
by the addition of a DMSO solution (20 μL) of trimethylorthosilicate (2 mg, 4.3 μmol). 
Fabrication of monodisperse RITC-NCs with other sizes can be similarly achieved by 
tuning the concentrations of TEOS, water, and ammonia. After the reaction was 
complete, without isolating the NCs, a methanol solution of RITC-
trimethylorthosilicate (10 mg/mL, 100 μL) was added to the silica NC solution. The 
mixture was stirred for 12 h in the dark. A methanol solution of mPEG-sil (10 mg/mL, 
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100 μL) was added. RITC-NCs were collected by centrifugation at 15k rpm, washed 
with ethanol (3 × 1 mL), and redispersed in DI water or 1× PBS buffer before use. 50 
 
3.2.4 hESC RITC-SNP Uptake  
Two wells of a 6 well plate of hESC H1s or WA01 OCT4 GFP KI H1 were plated 
into a 24 well plate coated with Matrigel a day or two before transfection. Y-27632 at 0x 
or 3x were added to the cells 4 hours before transfection. The RITC-SNP (30-40ug) 
were added to the wells and incubated for 2h. The cells were then washed with PBS 
(3x) and analyzed with flow cytometry. 
 
3.2.5 Sample preparation and flow cytometry analysis 
 Prior to analysis by flow cytometry, transfected cells on the 24-well plate were 
washed with 1 PBS (500 μL for each well) to remove any residual serum, dead cells and 
debris. Next, Accutase (100 µL) was added and incubated for 5-10 min to detach the cells 
from the plate. PBS (100 µL) was then added and pipetted up and down to break up cell 
clumps. A solution of 4% paraformaldehyde (100 µL) was added to fix the cells. Samples 
were kept in covered flow cytometry tubes until analysis (BD FACSCanto, Franklin Lakes, 
NJ, USA). 
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3.3 Results 
3.3.1 Cell morphological changes 
With the treatment of hESC colonies for 4h at varying concentrations of 0x, 1x, 
3x and 5x of the established working concentrations of Y-27632, the cells have 
significant morphological changes. At 0x, the cells maintain a tight 2D cobble stone like 
colony morphology, for the cells are tight and rounded up (Fig. 13). While at the 1x 
concentration treatment, the colonies have started to spread out and the cells start 
exhibiting fibroblastic like structures, elongating out, losing the rounded up structure. 
Then at 3x and 5x concentration treatments, the cells demonstrate to be significantly 
more spread out and elongated, to have relaxed their original structure, increasing the 
surface area and decreasing surface membrane tension.  
 
3.3.2 EGFP Transfection 
 Treatment and transfection using Fugene HD (FHD) were done on medium sized 
colonies at varying concentration of Y-27632 concentrations. With no treatment, the 
EGFP transfection efficiency demonstrated to be at 14.37%. With the 1x treatment of Y-
27632, the transfection efficiency increased to 17.64%, and as the concentration is 
increased to 3x and 5x, the respective efficiency increased to 22.74% and 26.41% 
(Fig.14). To verify the mechanism of spreading is due to the spreading and blebbing 
inhibition of the hESCs due to the importance of actin-myosin interactions, Blebbistatin, 
a downstream inhibitor of myosin was also used demonstrating an increase of FHD 
 33 
 
transfection of 17.75% at 10uM concentration (Fig.14).  The cells were transfected and 
imaged at 48 h post transfection and it can be seen that the transfection efficiency were 
substantially higher at 5x concentration of Y-27632 (Fig. 15).   
 The transfection efficiencies of FHD were also tested to determine the 
importance of when the cells were exposed and treated with Y-27632, before after or 
both. When the cells were pre-treated with Y-27632 4 h prior to transfection, the 
transfection efficiency was 28.85%, when the cells were treated with Y-27632 for four 
hours during the transfection with FHD, the transfection was 25.42% and when the cells 
were treated before and throughout transfection the efficiency was at 31.29% (Fig.16).   
 Cells were then passaged as single cells using 1x treatment of Y-27632 and 
transfected after 24 h. The cells were transfected with diblock PEG-PVBLG-8 FHD and 
Lipofectamine 2000, with transfection efficiency measured by flow cytometry to be 
exceptionally high with a 48.25%, 91.46% and 58.40% respectively (Fig. 17).  
In addition, after transfection using FHD, we found that the cells were still positive 
for SSEA4 72 hours post transfection (Fig. 18). In addition, a western blot conducted 4 
days post transfection demonstrates the expression of OCT4, a gene important for 
hESC pluripotency, in hESCs treated with Y-27632, blebbistatin and with and without 
EGFP transfection with FHD, demonstrating that this transfection process is only 
transient and the cell goes back to its natural pluripotent state (Fig. 19). 
 The transfection was also done testing another commercially available gene 
delivery agent Lipofectamine 2000 (Lip), which when not treated with Y-27632 and 
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treated with 5x Y-27632, the transfection efficiency obtained was 8.83% and 15.28%, 
respectively (Fig. 20). In addition, transfection of siRNA siGlo Green were demonstrated 
as well using Lipofectamine 2000 with the treatment of Y-27362 at 0x, 1x, and 3x 
concentrations with uptake efficiencies of 55.67%, 75.4% and 85.92%, respectively. 
Again demonstrating the effects of transfection efficiency enhancement of Y-27632 (Fig. 
21). 
 
3.3.3 Nanoparticle uptake 
 In the initial study 3 sizes of silica nanoparticles tagged with RITC  (RITC-SNP) 
were synthesized using the Stober method50, 200, 51 and 25 nm. Two sets of RITC-
SNP were synthesized one with and one without PEG surface modifications. These 
RITC-SNP were incubated for 2 h with the cells treated with 0x or 3x Y-27632. The 200, 
50 and 25nm sized RITC-SNP with PEG surface modification in cells untreated gave 
transfection efficiency of 6.79%, 12.55%, and 17.01%, respectively. While for the cells 
treated with 3x Y-27632, the efficiencies were 7.58%, 11.55% and 17.05% (Fig. 22). 
There is little to no increase for RITC-SNP uptake as measured by flow cytometry. Yet 
for the 200, 50, 25 nm sized RITC-SNP with no surface modifications the transfection 
efficiency without Y-27632 treatment was 70.03%, 86.54% and 86%, respectively. The 
transfection efficiencies for cells treated with 3x Y-27632 were 83.61%, 92.65% and 
94.53% (Fig. 23). These trends demonstrated higher uptake with the treatment or Y-
27632 in hESC, especially with the use of non-surface modified RITC-SNP. 
 35 
 
 
3.4 Discussion 
The treatment of hESC colonies with Y-27632 allowed the cells to transform its 
internal mechanical structure effectively by inhibiting its actin-mysoin contractility and 
cell to cell adhesion, thus allowing the cells to spread and decrease its membrane 
tension, mimicking a stiffer substrate and thus allowing an increase in endocytosis. We 
demonstrated a dose dependent effect of Y-27632 small molecule treatment in hESCs, 
where a 5x treatment increases transfection efficiency by 1.5-2 fold in both FHD and 
Lipofectamine 2000. It is important that the cells to be first transiently altered before 
transfection, spreading the cells and decreasing the membrane tension, readying the 
cells for efficient nanocomplex uptake. In our sequence dependence study of Y-27632 
addition, for treating the cells after transfection demonstrated to have only a slight 
transfection efficiency, while pre-treating the cells with Y-27632 increases transfection 
efficiency even more. Yet, the highest transfection efficiency was obtained while 
maintaining the treatment before and throughout the transfection. Through a series of 
transfections, we found that the smaller the colonies the larger the transfection 
efficiency (Data not shown). Adapting the previous procedures of passaging the cells as 
single cells using Y-27632 treatment before and after passaging and through the 
transfection, the transfection using FHD was extremely high at 91.46%.  
This procedure can be adapted to the use of other applications involving any 
endocytosis of nanocomplexes. With the treatment of Y-27632, siRNA delivery through 
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the use of Lipofectamine 2000 increases quite substantially, bringing the efficiency up to 
over 80%. But this is through the use of an analog siGlo Green, so future 
demonstrations of actual siRNA knockdown would be more informative. This also works 
for the use of nanoparticles, for without treatment of Y-27632, the smaller the particles 
of 25nm had a substantial increase in uptake efficiency than the larger particles sizes of 
50 and 200 nm. But there seemed to be a difference in uptake efficiency through the 
use of PEG and unmodified surface SNP, for with the use of PEG surface modification, 
there is little difference in the effect of the Y-27632 treatment on uptake efficiency. Yet 
for the unmodified surface RITC-SNP, there is an increase of uptake efficiency in all 
three sizes with the treatment of Y-27632.  
As previously reported49, the use of Y-27632 does not permanently effect the 
pluripotency and hESC cell state, for after 72 hours the cells go back to its natural tight 
2D colony morphology and expresses SSEA-4 and OCT4 as detected through cell 
staining and western blot, respectively. 
 
3.5 Conclusion 
We have studied and adapted a new procedure to transiently alter the pluripotent 
stem cell state to increase their susceptibility for uptake of nanocomplexes through 
endocytosis. The use of Y-27632 to treat hESC prior and during transfections effectively 
increases cell spreading and decrease cell membrane tension, as seen through RITC-
SNP and gene transfection complexes. The hESCs colonies were able to return to their 
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original morphology within hours after removing Y-27632 from the media and well 
maintains their pluripotency. We found that through the smaller the colony size to single 
cells, the higher the transfection efficiency.   
Here we demonstrated a new method of cell treatment using Y-27632 to treat 
hESC colonies before and during transfection. It allows for higher transfection efficiency 
in hESCs, opening the doors for the manipulation of pluripotent stem cells through 
transient gene therapy and diminishing an important hurdle for controlling and studying 
cells differentiation and development for many biomedical applications involving the use 
of pluripotent stem cells.  
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Scheme 1: plasmid DNA condensation by PEG-b-PVBLG-8 and the uptake and 
release of DNA inside the cell. 
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Scheme 2: The chemical route for preparation of PEG-b-PVBLG-8 from VB-Glu-NCA. 
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Table 1. PEG113-NH2 Initiated Polymerization of VB-Glu-NCA. 
Product M:Amine:TBDa Time (h) Conv. (%) Mn (Mn*) (× 103 g/mol)b MWD 
PEG113-b-PVBLG76 100:1:0.1 24 80 20.7 (24.6) 1.21 
PEG113-b-PVBLG287 400:1:0.1 60 78 75.3 (81.4) 1.29 
aTBD: 1,5,7-triazabicyclo[4.4.0]dec-5-ene; b the MW obtained (theoretical MW = Mn, PEG + 245.27 × 
conv. × [M]/[I]).  
 
 
 
Table 2. Synthesis and conformation analysis of PEG-b-PVBLG-8.a 
Starting Polymer Product Grafting Eff. (%)b 
[θ]222 (103deg 
cm2/dmol)c 
Helical 
Content (%)d 
PEG113-b-PABLG76 
PEG113-b-PVBLG76-8 
(PEV-L) 
> 95 32.8 91.8 
PEG113-b-PABLG287 
PEG113-b-PVBLG287-
8 (PEV-H) 
> 95 34.6 96.4 
a Reducing reagent (5 molar equiv) was used.  Reaction was carried out for 48 h at 50oC.    bThe grafting 
efficiency was determined by 1H NMR analysis; cThe mean residue molar ellipticity was calculated by 
following literature-reported formulas: Ellipticity ([θ]222 nm in cm2 deg dmol−1) = (millidegrees × mean 
residue weight)/(path length in millimeters × concentration of polypeptide in mg mL−1); dThe α-helix 
contents of the polypeptides were calculated using the following equation: % α-helix = (-[]222 + 
3000)/39,000.42 
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Figure 1: (a) CD spectra in water of PEV-L,PEV-H, DNA/PEV-L, and DNA/PEV-H at 
1:40 weight ratio at pH 3. (b) The pH dependence of the residue molar ellipticity at 222 
nm for PEV-L and PEV-H at 0.05 mg/mL. (c) Salt dependence of residue ellipticity at 
222 nm for PEV 
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Figure 2: DNA/Polymer complex analysis: Gel Retardation of the PEV-L at 
different DNA to polymer weight ratios. 
Figure 3: TEM image of PEV-L with DNA 
nanocomplex. Scale bar: 200 nm 
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Figure 4: Particle size analysis of the PEV-L copolymer and DNA complex with different 
PVBLG-8 chain lengths and DNA to polymer weight ratios. 
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Figure 5: Particle size analysis of the PEV-L copolymer and DNA complex with different 
PVBLG-8 chain lengths and DNA to polymer weight ratios. 
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Figure 6: In-vitro analysis in IMR90 cells. MTT cell viability assay of the DNA/polymer 
nanocomplex with different polymers and at different weight ratios in IMR90. 
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Figure 7: Initial testing for PEV-L along with Lipofectamine 2000 (Lip) and PVBLG-8 (P0) with 
varying pEGFP-N1 plasmid and polymer amount. Transfection efficiency was analyzed 48 hours 
post transfection with flow cytometry. 
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Figure 8: Fluorescent images of the transfection using Lipofectamine and PEV-H. Scale Bars 
0.25 mm 
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Figure 9: EGFP plasmid transfection efficiency using Lipofectamine 2000 and PEV-H of hESC 
H1 as small colonies 
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Figure 10: EGFP plasmid transfection efficiency using Lipofectamine 2000 and PEV-H of hESC 
H1 as single cells as analysed by flow cytometry. 
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Oct4 
Alpha Tubulin 
Figure 11: Western blot of cells isolated 72 h post transfection 
demonstrating the protein expression of OCT4 in hESC H1 cells. 
 51 
 
N
e
g
a
ti
v
e
 
P
E
V
-H
 
Colonies Single Cells 
B
ri
g
h
t 
fi
e
ld
 
H
o
e
c
h
s
t 
S
S
E
A
-4
 
G
F
P
 
N
e
g
a
ti
v
e
 
P
E
V
-H
 
F
ig
u
re
 1
2
: 
B
ri
g
h
t 
fi
e
ld
 a
n
d
 f
lu
o
re
s
c
e
n
c
e
 i
m
a
g
in
g
 o
f 
P
E
V
-H
 t
ra
n
s
fe
c
ti
o
n
 o
f 
E
G
F
P
 p
la
s
m
id
 i
n
to
 h
E
S
C
 a
s
 c
o
lo
n
ie
s
 a
n
d
 
s
in
g
le
 c
e
lls
. 
C
o
lo
n
ie
s
 w
e
re
 s
ta
in
e
d
 w
it
h
 H
o
e
c
h
s
t 
a
n
d
 p
lu
ri
p
o
te
n
c
y
 m
a
rk
e
r 
S
S
E
A
-4
 a
n
ti
b
o
d
y
 c
o
n
ju
g
a
te
d
 w
it
h
 P
E
. 
S
c
a
le
 B
a
r:
 2
5
0
 µ
m
 
 52 
 
  
0X  1X 
3X 5X 
Figure 13: Brightfield imaging of hESCs morphological change after 4 h treatment with 
varying concentrations of Y-27632 for 4 h. Scale bar-250 um 
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Figure 14: Flow Cytometry data analysis for H1 hESC transfection with DNA and Fugene HD 
with varying concentrations of Y-27632 and Blebbistatin. 
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Figure 15: Fluorescence imaging of 0X, 1X, 5X Y-27632 with Fugene HD with EGFP 
plasmid 
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Figure 16: Figure caption: Flow Cytometry data analysis for H1 hESC transfection with Fugene 
HD at 5x treatment of Y-27632 for 4 h before transfection, for 4 h after transfection and then 
before and throughout transfection.  
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Figure 17: Flow Cytometry data analysis for Y-27532 treated single cell passaging of H1 hESC 
transfection with Diblock, FHD, and Lipofectamine 2000. 
48.25
91.46
58.40
0
10
20
30
40
50
60
70
80
90
100
%
 G
FP
 P
o
si
ti
ve
 57 
 
  
DAPI SSEA-4 GFP 10
x 
10x 
10
x 
10x 
10
x 
10x 
FHD 
Figure 18: DAPI and SSEA4 staining of Fugene HD transfection of EGFP of Y-27632 treated 
single cells of hESCs. 
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Figure 19: Western blot demonstrating the retention of pluripotency of cells after Y-27632 
treatment and transfection 4 days post transfection. 
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Figure 20: Flow Cytometry data analysis for H1 hESC transfection with DNA and Lipofectamine 
with varying concentrations of Y-27632. 
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Figure 21: Flow Cytometry of siGlo Green (siRNA analog) using Lipofectamine, after 3 h Y-
27632 incubation. 
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Figure 22: Flow Cytometry data analysis of hESC with and without treatment of Y-27632 with 
different sizes of SNP tagged with RITC with PEG surface modification.  2 hr incubation  
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Figure 23: Flow Cytometry data analysis of hESC with and without treatment of Y-27632 with 
different sizes of SNP tagged with RITC without surface modification.  5 h incubation 
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